Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Giant Cell Tumor of Tendon Sheath 5Synovitis, Pigmented Villonodular 3Melanoma 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × pexidartinib × Clear all
NCT01349049 2020-03-02

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1/2 Completed
90 enrolled 23 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡